The Ergogenic Effect of Recombinant Human Erythropoietin on V̇O 2 max Depends on the Severity of Arterial Hypoxemia

Paul Robach, Jose A. L. Calbet, Jonas J. Thomsen et al. · 2008

Read The Ergogenic Effect of Recombinant Human Erythropoietin on V̇O 2 max Depends on the Severity of Arterial Hypoxemia by Paul Robach, Jose A. L. Calbet, Jonas J. Thomsen et al. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0002996.txt.

Description

Paul Robach, Jose Calbet, Jonas Thomsen and co-authors tested how low oxygen changes the benefit of erythropoietin in 2008. Treatment with recombinant human erythropoietin raises the blood's oxygen-carrying capacity and clearly boosts maximal oxygen uptake in normal air. In severe acute hypoxia, low oxygen, that boost had not appeared.

The PLOS ONE study finds the ergogenic effect on maximal oxygen uptake depends on how severe the hypoxemia is. That nuance matters for altitude physiology and for sport, where the hormone is both a therapy and a banned doping agent. It defines when extra red cells stop helping.

Catalog record

CREATORPaul Robach, Jose A. L. Calbet, Jonas J. Thomsen et al.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE59 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0002996

Browse the full library · About the Tower of Babel